Curis Lifesciences Soars: 76% Revenue Jump!

Curis Lifesciences has announced a significant financial performance, with revenue climbing 76% year-on-year to Rs 28 crore. This substantial growth was complemented by a 91% increase in Profit After Tax (PAT), attributed to stringent cost control measures and optimized interest expenses. The company, supported by investor Mukul Agrawal, is poised for continued expansion.

With over 75% revenue jump in the first half of the current fiscal year, Curis Lifesciences is focusing on expanding its international presence. The company is actively seeking approvals in markets including Nigeria, Kenya, Yemen, and the Philippines. This strategic push aims to accelerate exports to the Middle East and Africa in the upcoming financial year, alongside developing specialty formulations and entering new therapeutic areas for enhanced profitability.

Funds raised recently are being strategically allocated to enhance operational capabilities, including facility upgrades and storage construction. Furthermore, the company is committed to debt repayment and securing international registrations. Curis Lifesciences anticipates steady growth, bolstered by existing partnerships and a broad client base, as it navigates its expansion into new global markets.